- Previous Close
15,250.00 - Open
14,770.00 - Bid 14,010.00 x --
- Ask 14,050.00 x --
- Day's Range
13,840.00 - 14,855.00 - 52 Week Range
8,290.00 - 24,150.00 - Volume
654,421 - Avg. Volume
1,681,309 - Market Cap (intraday)
248.385B - Beta (5Y Monthly) 0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield 100.00 (0.71%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, urinary incontinence, prostatic hyperplasia, pregnancy, bug bite, anthelmintics, and cosmetic care, as well as vitamins and minerals, tonics, nutrition products. It also provides transdermal drug delivery system, a pharmaceutical preparation that is applied to the intact skin for systemic absorption; and active pharmaceutical ingredients. The company also exports its products to approximately 22 countries, including Asia, South America, the Middle East, and Africa. DAE HWA Pharmaceutical Co., Ltd. was founded in 1984 and is headquartered in Seoul, South Korea.
www.dhpharm.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 067080.KQ
View MorePerformance Overview: 067080.KQ
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 067080.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 067080.KQ
View MoreValuation Measures
Market Cap
248.39B
Enterprise Value
339.80B
Trailing P/E
472.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.68
Price/Book (mrq)
3.45
Enterprise Value/Revenue
2.27
Enterprise Value/EBITDA
25.40
Financial Highlights
Profitability and Income Statement
Profit Margin
9.33%
Return on Assets (ttm)
2.12%
Return on Equity (ttm)
11.26%
Revenue (ttm)
115.31B
Net Income Avi to Common (ttm)
10.76B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
9.83B
Total Debt/Equity (mrq)
62.50%
Levered Free Cash Flow (ttm)
-6.4B